Luminex (LMNX)Kelly Sullivan & Tina Xue

Company Overview

� Founded in 1995 and IPO in 2000

� Develops, manufactures and markets innovative biological testing technologies with applications throughout the clinical diagnostic and life science industries.

� xMAP® xTAG® MultiCode®

Stock Overview

� Current Price: $16.86

� Market Cap: 700.79M

� 52 Week: 15.58 - 25.79

� P/E ratio: 58.1362

� Enterprise Value/EBITDA: 16.88

� Beta: 0.67

� Cash: 41.6M

� Debt: 2.85M

Stock Overview

� 5 year stock chart

Stock Overview

� 1 year stock chart

Focused, Accurate, and Reliable Product Line

� xTag, Multicode, xMAP, (up to 9600 results in 1hr)

� Dynamic

� Broad range of applications

� Diagnostic, clinical research, biodefense, genetic analysis

� FlexMap3D

� Patents (at least ten this year)

Key Partnerships

� Life Science Research Partners

� Clinical Diagnostic Partners

� Certified Developer Program

� Customizable Kits

Key Partnerships

Key Partnerships

� Case Study

� Life Technologies: "Life Technologies is a global biotechnology company headquartered in Carlsbad, California. It possesses a portfolio of more than 9 million genetic research assays and custom solutions”

� Luminex: Provide flexible, long longevity xMAP® multiplex platform

� Life Technologies produces:

� Premixed Luminex® assay panels

� single-target Luminex® bead kits

� Custom Luminex® assay panels

Expansion

� Through existing partners

� Entering new segments and expanding

� Biodefense and life sciences

� Defense Threat Reduction Agency (DTRA)

� Gastrointestinal Pathogen Panel (GPP)

Industry

� Increase in aging population

� Increase in R&D spending by US based Pharmaceutical Companies and Foreign Governments

� China and India

� global pharmaceuticals market is worth US$300 billion/year, a figure expected to rise to US$400 billion within three years.

Misperceptions

� lower-margin real-time testing products

Reality:

1. Luminex’s buyout of privately-held diagnostic testing company EraGen Biosciences--highly complementary portfolio of molecular diagnostic tests based on the MultiCode platform

2. Latest offering: the xTAG Gastrointestinal Pathogen Panel (GPP) molecular test. The device allows fast and simultaneous detection of 95% of bacterial, viral and gastroenteritis pathogens in a single test

3. Received a Technology Award from the Austin Chamber of Commerce in September 2012

Misperceptions

� Overreaction to Luminex’s acquisition of GenturaDx:

•Luminex’s share prices to fall nearly 18% after announcing the acquisition of $50 million and its market cap to fall some $180 million on the day.

•People believe the mismatch between the levels of complexity between the two companies product would lead to Luminex’s profit margin to shrink.

�Clinical labs of all size worldwide.

�Complete solution for molecular diagnostic customers across assay types and plex size.

�Simple to use

Catalysts

� 1. The company is currently seeking the Food and Drug Administration (FDA) approval for both NeoPlex4 and the GPP assay and plans to launch the devices in the U.S. around year-end 2012 and early 2013, respectively.

� 2. Luminex announced its plans to expand its Life Science and Biodefense Groups

Risks

� Strength of partners will effect Luminex business

� Intellectual property rights

� Inorganic growth trend

Questions?